This Notice of Funding Opportunity (NOFO) supports the optimization of promising genome editing-based therapeutic leads for Alzheimer's Disease-Related Dementias (ADRD), by advancing therapeutic candidates towards IND-enabling studies. It supports the development of therapeutic lead(s) that show potential as genome editing therapeutics, as evidenced by convincing proof-of-concept studies in appropriate models. At the end of the funding period, successful projects will have delivered an optimized therapeutic candidate, ready for initiating IND-enabling studies.
This NOFO is not specific for any one or group within the ADRD spectrum of disorders. ADRD include: Frontotemporal dementia (FTD), Lewy body dementias (LBD) (including Dementia with Lewy bodies (DLB), Parkinson Disease Dementia (PDD)), Vascular Contributions to Cognitive Impairment and Dementia (VCID), and Multiples Etiology Dementias (MED).
Deadlines:
RFA-NS-24-037 Expiration Date November 20, 2024
Sponsor Institute/Organizations: National Institutes of Health
Address: National Institutes of Health; 31 Center Drive; MSC 2220; Bethesda; MD 20892-2220; USA
Nov 19, 2024
$5,000,000
Affiliation: National Institutes of Health
Address: National Institutes of Health; 31 Center Drive; MSC 2220; Bethesda; MD 20892-2220; USA
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.